Nutrition 21, Inc.   Report issue

For profit Phase 2
Founded: Purchase NY United States (2012)
Status: Left NME R&D (2018)

Organization Overview

First Clinical Trial
2012
NCT00289354
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Nutrition 21, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

chromium tripicolinate (4 trials)

Drugs in Other Trials (5)

arginine (1 trial)

biotin (3 trials)

fish oil (Omegavan) (1 trial)

lactobacillus casei (1 trial)

silicon (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Body Weight (Phase 2)

Weight Gain (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 6